WESTBOROUGH, Mass.--(BUSINESS WIRE)--PharmaVigilant announced today that Cleveland Biolabs has selected the InSpire EDC system for its upcoming Phase II trial. “We chose InSpire because it provides us unprecedented access to our data, not only during the trial but throughout our development program. The I- Warehouse reporting tool offers us the access to our data that we need during our early stages of development.” said John Gordon, Director Clinical Development for Cleveland Biolabs.
